Gemcitabine has also been shown to play a variety of immune modulatory effects in cancer (44), such as depleting Tregs (60), improving CD8+/CD4+ T-cell infiltration (61), depleting immune suppressive myeloid populations (62) and improving tumor cell sensitization to immune recognition (63, 64). The gene discussed is CD8A; the disease is cancer.